By Jaime Llinares Taboada


AstraZeneca PLC on Monday reported positive Phase 3 trial results for its Enhertu treatment on breast cancer patients.

The pharmaceutical giant said that Enhertu demonstrated meaningful survival improvement in patients with breast cancer compared with physician's choice of chemotherapy.

"Today's historic news from DESTINY-Breast04 could reshape how breast cancer is classified and treated. A HER2-directed therapy has never-before shown a benefit in patients with HER2-low metastatic breast cancer," Susan Galbraith, AstraZeneca's executive vice president for Oncology R&D, said.

The HER2 protein is expressed on the surface of many types of tumors, and is one of many biomarkers expressed in breast cancer tumors.

"These results for Enhertu are a huge step forward and could potentially expand our ability to target the full spectrum of HER2 expression, validating the need to change the way we categorise and treat breast cancer," she said.

The DESTINY-Breast04 trial enrolled around 540 patients in Asia, Europe and North America.


Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT


(END) Dow Jones Newswires

02-21-22 0237ET